Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Director · CEO | March 17, 2026 | March 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytomX Therapeutics, Inc.
Report date March 17, 2026 · Filed March 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,078,922 |
Reported balance
After 2026-03-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-17 · Sale · Disposed 118,969 · Balance 1,078,922 F1: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2: Includes 457,500 RSUs. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 93,158 |
Reported balance
Holding disclosure · report date 2026-03-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 93,158 F3: Shares held by Sean A. McCarthy 2018 Trust, of which Reporting Person is trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs").
F2: Includes 457,500 RSUs.
F3: Shares held by Sean A. McCarthy 2018 Trust, of which Reporting Person is trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2021 Filed Jun 17, 2021 01:49 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001567619-21-012252 · doc1.xml · derivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,113 Underlying: Common Stock · 30 shares Expires 2021-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| June 14, 2021 Filed Jun 17, 2021 01:49 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 10 | $0.95 | $9.45 |
DisclosureSEC source: 0001567619-21-012252 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2021 Filed Jun 17, 2021 01:49 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 30 | $1.13 | $34.02 |
DisclosureSEC source: 0001567619-21-012252 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 21:37 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001567619-21-007541 · doc1.xml · derivative · entry 3 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,143 Underlying: Common Stock · 100,000 shares Expires 2021-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 21:37 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 100,000 | $7.49 | $749,470.00 |
DisclosureSEC source: 0001567619-21-007541 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,894 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $7.35 to $7.62, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 21:37 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 100,000 | $1.13 | $113,390.00 |
DisclosureSEC source: 0001567619-21-007541 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 21:58 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $7.85 | $0.00 |
DisclosureSEC source: 0001567619-21-005396 · doc1.xml · derivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-02-26 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 26, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:58 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $7.85 | $0.00 |
DisclosureSEC source: 0001567619-21-005396 · doc1.xml · derivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2031-02-25 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 26, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| December 23, 2020 Filed Dec 29, 2020 00:52 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001567619-20-021619 · doc1.xml · derivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,143 Underlying: Common Stock · 100,000 shares Expires 2021-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| December 23, 2020 Filed Dec 29, 2020 00:52 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 100,000 | $1.13 | $113,390.00 |
DisclosureSEC source: 0001567619-20-021619 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2020 Filed Dec 7, 2020 21:58 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 930 | $6.39 | $5,944.56 |
DisclosureSEC source: 0001567619-20-020707 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,894 F1 · kind: 930 shares were acquired pursuant to the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 20:53 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,500 | $0.00 Strike: $6.61 | $0.00 |
DisclosureSEC source: 0001567619-20-017051 · doc1.xml · derivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,500 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. F2 · balance_after: The Reporting Person previously transferred an aggregate of 738,586 shares underlying certain stock options, including 417,802 shares subject to this stock option, to an immediate family member. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 20:53 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 20,500 | $6.61 | $135,601.35 |
DisclosureSEC source: 0001567619-20-017051 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 20:54 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 1,158 | $5.11 | $5,915.64 |
DisclosureSEC source: 0001567619-20-011542 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,464 F1 · kind: 1,158 shares were acquired pursuant to the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:31 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001567619-20-010115 · doc1.xml · derivative · entry 3 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,143 Underlying: Common Stock · 36,000 shares Expires 2021-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:31 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 36,000 | $15.00 | $540,000.00 |
DisclosureSEC source: 0001567619-20-010115 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,306 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:31 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 36,000 | $1.13 | $40,820.40 |
DisclosureSEC source: 0001567619-20-010115 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 23:37 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $7.13 | $0.00 |
DisclosureSEC source: 0001567619-20-004345 · doc1.xml · derivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2030-02-13 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| November 30, 2019 Filed Dec 16, 2019 21:20 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 1,080 | $5.32 | $5,746.68 |
DisclosureSEC source: 0001567619-19-023150 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,306 F1 · kind: 1,080 shares were acquired pursuant to the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 30, 2019 Filed Jun 8, 2021 17:10 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GiftCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-011808 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,809 F1 · balance_after: Includes 1,006 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 31, 2021 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). F2 · balance_after: Amount of securities directly held has been adjusted to reflect the transfer of (i) 2,473 shares pursuant to a domestic relations order on July 9, 2018, (ii) 193,118 shares to Sean A. McCarthy 2018 Trust. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 20:04 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 695 | $8.21 | $5,706.65 |
DisclosureSEC source: 0001567619-19-012666 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,226 F1 · kind: 695 shares were acquired pursuant to the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 23:56 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $16.85 | $0.00 |
DisclosureSEC source: 0001567619-19-001862 · doc1.xml · derivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2029-01-24 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2019 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| November 30, 2018 Filed Dec 6, 2018 18:57 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 468 | $11.73 | $5,489.64 |
DisclosureSEC source: 0001567619-18-007415 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,531 F1 · kind: 468 shares were acquired pursuant to the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 02, 2018 Filed Nov 5, 2018 21:14 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,156 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001567619-18-005081 · doc1.xml · derivative · entry 7 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,071 Underlying: Common Stock · 1,156 shares Expires 2025-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · derivative.exercise_date: This option vests in 48 substantially equal monthly installments starting on the last day of January 2015. Read SEC document |
| November 02, 2018 Filed Nov 5, 2018 21:14 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 1,156 | $15.01 | $17,348.09 |
DisclosureSEC source: 0001567619-18-005081 · doc1.xml · nonDerivative · entry 5 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,063 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades in prices ranging from $15.00 to $15.02, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 02, 2018 Filed Nov 5, 2018 21:14 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 1,156 | $1.57 | $1,820.58 |
DisclosureSEC source: 0001567619-18-005081 · doc1.xml · nonDerivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 21:14 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,370 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001567619-18-005081 · doc1.xml · derivative · entry 6 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,227 Underlying: Common Stock · 5,370 shares Expires 2025-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · derivative.exercise_date: This option vests in 48 substantially equal monthly installments starting on the last day of January 2015. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 21:14 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 5,270 | $15.00 | $79,050.00 |
DisclosureSEC source: 0001567619-18-005081 · doc1.xml · nonDerivative · entry 3 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,063 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 21:14 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 100 | $15.01 | $1,500.50 |
DisclosureSEC source: 0001567619-18-005081 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,333 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 21:14 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 5,370 | $1.57 | $8,457.21 |
DisclosureSEC source: 0001567619-18-005081 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 23:14 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,052 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001567619-18-002231 · doc1.xml · derivative · entry 3 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,597 Underlying: Common Stock · 13,052 shares Expires 2025-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · derivative.exercise_date: This option vests in 48 substantially equal monthly installments starting on the last day of January 2015. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 23:14 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 13,052 | $21.86 | $285,342.82 |
DisclosureSEC source: 0001567619-18-002231 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,063 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $21.65 to $22.39, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 23:14 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 13,052 | $1.57 | $20,555.59 |
DisclosureSEC source: 0001567619-18-002231 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 22:15 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,497 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001140361-18-031945 · doc1.xml · derivative · entry 3 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,649 Underlying: Common Stock · 4,497 shares Expires 2025-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · derivative.exercise_date: This option vests in 48 substantially equal monthly installments starting on the last day of January 2015. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 22:15 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 4,497 | $25.06 | $112,688.52 |
DisclosureSEC source: 0001140361-18-031945 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,063 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $25.00 to $25.23, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 22:15 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 4,497 | $1.57 | $7,082.33 |
DisclosureSEC source: 0001140361-18-031945 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| July 03, 2018 Filed Jul 6, 2018 22:52 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,028 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001140361-18-031810 · doc1.xml · derivative · entry 3 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,146 Underlying: Common Stock · 2,028 shares Expires 2025-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · derivative.exercise_date: This option vests in 48 substantially equal monthly installments starting on the last day of January 2015. Read SEC document |
| July 03, 2018 Filed Jul 6, 2018 22:52 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 2,028 | $25.09 | $50,880.49 |
DisclosureSEC source: 0001140361-18-031810 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,063 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $25.00 to $25.21, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 03, 2018 Filed Jul 6, 2018 22:52 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 2,028 | $1.57 | $3,193.90 |
DisclosureSEC source: 0001140361-18-031810 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 22:50 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,052 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001140361-18-031327 · doc1.xml · derivative · entry 3 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,174 Underlying: Common Stock · 13,052 shares Expires 2025-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · derivative.exercise_date: This option vests in 48 substantially equal monthly installments starting on the last day of January 2015. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 22:50 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 13,052 | $23.42 | $305,707.86 |
DisclosureSEC source: 0001140361-18-031327 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,063 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades in prices ranging from $22.56 to $23.68, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Share numbers reflect the transfer of (i) 77,118 shares to the reporting person and (ii) 77,119 shares to the reporting person's ex-wife, from McCarthy Family Trust dated August 9, 2001, Sean A. McCarthy and Jeanette J. McCarthy, Trustees, pursuant to a domestic relations order. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 22:50 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 13,052 | $1.57 | $20,555.59 |
DisclosureSEC source: 0001140361-18-031327 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · balance_after: Share numbers reflect the transfer of (i) 77,118 shares to the reporting person and (ii) 77,119 shares to the reporting person's ex-wife, from McCarthy Family Trust dated August 9, 2001, Sean A. McCarthy and Jeanette J. McCarthy, Trustees, pursuant to a domestic relations order. Read SEC document |
| May 31, 2018 Filed Jun 5, 2018 23:45 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 302 | $17.90 | $5,406.10 |
DisclosureSEC source: 0001140361-18-027474 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,945 F1 · shares: The shares were acquired under the issuer's Employee Stock Purchase Plan on May 31, 2018. Read SEC document |
| May 01, 2018 Filed May 2, 2018 22:25 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,578 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001140361-18-021344 · doc1.xml · derivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,226 Underlying: Common Stock · 19,578 shares Expires 2025-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · derivative.exercise_date: This option vests in 48 substantially equal monthly installments starting on the last day of January 2015 Read SEC document |
| May 01, 2018 Filed May 2, 2018 22:25 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 19,578 | $26.55 | $519,743.04 |
DisclosureSEC source: 0001140361-18-021344 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,643 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $26.22 to $26.77, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 01, 2018 Filed May 2, 2018 22:25 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 19,578 | $1.57 | $30,833.39 |
DisclosureSEC source: 0001140361-18-021344 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,221 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 62 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001140361-18-012008 · doc1.xml · derivative · entry 8 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,752 Underlying: Common Stock · 62 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001140361-18-012008 · doc1.xml · derivative · entry 7 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,143 Underlying: Common Stock · 9,000 shares Expires 2021-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,516 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001140361-18-012008 · doc1.xml · derivative · entry 6 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,804 Underlying: Common Stock · 10,516 shares Expires 2025-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option vests in 48 substantially equal monthly installments starting on the last day of January 2015. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 19,578 | $29.43 | $576,141.38 |
DisclosureSEC source: 0001140361-18-012008 · doc1.xml · nonDerivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,643 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.90, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.